Ionis Pharmaceuticals, Inc. Common Stock
Veridion Score
Composite trend over time
Why is IONS moving today?
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for IONS.
IONS insider activity
Ionis Pharmaceuticals, Inc. Common Stock
5 insiders bought in the last 90 days
Net selling: -$53.2M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-26 | 2026-06-26 | Monia Brett P | Insider | sell | $80.59 | 50,000 | 245,571 | $4.0M | SEC Form 4 |
| 2026-06-26 | 2026-06-26 | Monia Brett P | Insider | buy | $56.78 | 50,000 | 295,571 | $2.8M | SEC Form 4 |
| 2026-06-26 | 2026-06-25 | Swayze Eric | Insider | sell | $79.18 | 10,602 | 21,759 | $839K | SEC Form 4 |
| 2026-06-26 | 2026-06-25 | Monia Brett P | Insider | sell | $78.49 | 21,072 | 245,571 | $1.7M | SEC Form 4 |
| 2026-06-26 | 2026-06-25 | Monia Brett P | Insider | buy | $32.60 | 21,072 | 266,643 | $687K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 129 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moIONS contract awards, year to date.
Public federal awards linked to this ticker.
IONS lobbying filings, year to date.
Registered lobbying filings matched to Ionis Pharmaceuticals, Inc. Common Stock.